Ares Financial Consulting’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.52K Hold
5
– – ﹤0.01% 835
2026
Q2
$2.68K Buy
+5
New +$2.56K ﹤0.01% 841

Other funds holding MDGL

Ares Financial Consulting's MDGL Position: Q3 2026 in Review

Ares Financial Consulting held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2026 at 5 shares worth $2.52K. The position accounts for ﹤0.01% of the portfolio, ranked #835.

Ares Financial Consulting first reported a position in MDGL in Q2 2026 and has held it in 2 quarters since. The position peaked at $2.68K in Q2 2026. 434 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Ares Financial Consulting held 5 shares of Madrigal Pharmaceuticals worth $2.52K as of Q3 2026.
  • Ares Financial Consulting left its Madrigal Pharmaceuticals share count unchanged in Q3 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #835 holding.
  • Ares Financial Consulting first reported a position in Madrigal Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Ares Financial Consulting's Madrigal Pharmaceuticals position peaked at $2.68K in Q2 2026.
  • 434 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.